Sugi Predict

Sugi Predict / Compounds / SCHEMBL21807233

SCHEMBL21807233

SCHEMBL21807233

Cn1c(=O)cc(Cl)c2ccncc21

nearest known ligand 0.42

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ ADORA3 P0DMS8 2/20 0.42
▸ ADORA2A P29274 2/20 0.42
▸ ROCK2 O75116 3/20 0.42
▸ CYP19A1 P11511 1/20 0.38
▸ NFATC1 O95644 1/20 0.38
▸ GSK3B P49841 1/20 0.38
▸ DYRK1A Q13627 1/20 0.38
▸ KDM4E B2RXH2 1/20 0.38
▸ NQO2 P16083 1/20 0.38
▸ AAK1 Q2M2I8 3/20 0.37
▸ GRM4 Q14833 1/20 0.37
▸ ADORA1 P30542 1/20 0.36
▸ CD38 P28907 1/20 0.36
▸ BCL6 P41182 1/20 0.36
▸ KDM5A P29375 1/20 0.35
▸ KDM4C Q9H3R0 1/20 0.35
▸ HSD17B10 Q99714 1/20 0.35
▸ HIPK2 Q9H2X6 1/20 0.35
▸ LMNA P02545 1/20 0.35
▸ MAPT P10636 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL21807514 0.80 KDM4E (0.53) ADORA3ADORA2AROCK2NFATC1GSK3B
SCHEMBL829976 0.75 KDM4E (0.65) KDM4ENQO2HSD17B10LMNAMAPT
SCHEMBL29891972 0.75 KDM4E (0.65) KDM4ENQO2HSD17B10LMNAMAPT
SCHEMBL30727441 0.74 MAT2A (0.50) KDM4ENQO2GRM4HSD17B10LMNA
SCHEMBL1609661 0.73 ADORA3 (0.54) ADORA3ADORA2AROCK2NFATC1GSK3B
SCHEMBL19946167 0.73 AAK1 (0.54) ADORA3ADORA2AROCK2CYP19A1AAK1
SCHEMBL19946155 0.72 ROCK2 (0.58) ROCK2AAK1
SCHEMBL31227905 0.72 DYRK1A (0.59) ADORA3ADORA2AROCK2CYP19A1NFATC1
SCHEMBL30507475 0.71 ALDH1A1 (0.50) KDM4ENQO2HSD17B10MAPTHPGD
SCHEMBL28497698 0.71 ALDH1A1 (0.50) KDM4ENQO2HSD17B10MAPTHPGD

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-113939295-B Pyridazinones and methods of use thereof 金翅雀生物公司 2025-05-16 — — CN disclosed
EP-4414365-A1 PYRIDAZINONES AND METHODS OF USE THEREOF Goldfinch Bio, Inc. (US) 2024-08-14 — — EP disclosed
EP-3852533-B1 PYRIDAZINONES AND METHODS OF USE THEREOF GOLDFINCH BIO INC (US) 2024-02-28 — — EP disclosed
US-20220152031-A1 PYRIDAZINONES AND METHODS OF USE THEREOF GOLDFINCH BIO, INC. 2022-05-19 — — US disclosed
US-20220152031-A1 PYRIDAZINONES AND METHODS OF USE THEREOF GOLDFINCH BIO, INC. 2022-05-19 — — US disclosed
US-20220024917-A1 PYRIDAZINONES AND METHODS OF USE THEREOF GOLDFINCH BIO, INC. 2022-01-27 — — US disclosed
US-20220024917-A1 PYRIDAZINONES AND METHODS OF USE THEREOF GOLDFINCH BIO, INC. 2022-01-27 — — US disclosed
EP-3941475-A1 PYRIDAZINONES AND METHODS OF USE THEREOF Goldfinch Bio, Inc. (US) 2022-01-26 — — EP disclosed
CN-113939295-A Pyridazinones and methods of use thereof 金翅雀生物公司 2022-01-14 — — CN disclosed
EP-3852533-A1 PYRIDAZINONES AND METHODS OF USE THEREOF Goldfinch Bio, Inc. (US) 2021-07-28 — — EP disclosed
US-11046690-B2 Pyridazinones and methods of use thereof GOLDFINCH BIO, INC. (US) 2021-06-29 — — US disclosed
US-11046690-B2 Pyridazinones and methods of use thereof GOLDFINCH BIO, INC. (US) 2021-06-29 — — US disclosed
CN-112911935-A Pyridazinones and methods of use thereof 金翅雀生物公司 2021-06-04 — — CN disclosed
WO-2020191056-A1 PYRIDAZINONES AND METHODS OF USE THEREOF GOLDFINCH BIO, INC. (US) 2020-09-24 — — WO disclosed
US-20200283437-A1 PYRIDAZINONES AND METHODS OF USE THEREOF GFB (ABC), LLC 2020-09-10 — — US disclosed
US-20200283437-A1 PYRIDAZINONES AND METHODS OF USE THEREOF GFB (ABC), LLC 2020-09-10 — — US disclosed
US-10654850-B2 Pyridazinones and methods of use thereof GOLDFINCH BIO, INC. (US) 2020-05-19 — — US disclosed
US-10654850-B2 Pyridazinones and methods of use thereof GOLDFINCH BIO, INC. (US) 2020-05-19 — — US disclosed
US-20200102301-A1 PYRIDAZINONES AND METHODS OF USE THEREOF GFB (ABC), LLC 2020-04-02 — — US disclosed
WO-2020061162-A1 PYRIDAZINONES AND METHODS OF USE THEREOF GOLDFINCH BIO, INC. (US) 2020-03-26 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20220024917-A1 PYRIDAZINONES AND METHODS OF USE THEREOF ATP6V1B1, GLS, REN ADORA3 534/4885ADORA2A 351/4885ROCK2 3190/4885
US-20220152031-A1 PYRIDAZINONES AND METHODS OF USE THEREOF GLS, ATP6V1B1, PDXK ADORA3 839/4885ADORA2A 339/4885ROCK2 2943/4885
US-20200102301-A1 PYRIDAZINONES AND METHODS OF USE THEREOF ATP6V1B1, GLS, REN ADORA3 534/4885ADORA2A 351/4885ROCK2 3190/4885
US-11046690-B2 Pyridazinones and methods of use thereof ATP6V1B1, GLS, REN ADORA3 534/4885ADORA2A 351/4885ROCK2 3190/4885
US-20200283437-A1 PYRIDAZINONES AND METHODS OF USE THEREOF ATP6V1B1, GLS, REN ADORA3 534/4885ADORA2A 351/4885ROCK2 3190/4885
US-10654850-B2 Pyridazinones and methods of use thereof ATP6V1B1, GLS, REN ADORA3 534/4885ADORA2A 351/4885ROCK2 3190/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.